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MicroRNA-155 contributes 
to shear-resistant leukocyte adhesion to human 
brain endothelium in vitro
Camilla Cerutti1,3*, Patricia Soblechero‑Martin1, Dongsheng Wu1,4, Miguel Alejandro Lopez‑Ramirez1,5, 
Helga de Vries6, Basil Sharrack2, David Kingsley Male1 and Ignacio Andres Romero1
Abstract 
Background: Increased leukocyte adhesion to brain endothelial cells forming the blood–brain barrier (BBB) precedes 
extravasation into the central nervous system (CNS) in neuroinflammatory diseases such as multiple sclerosis (MS). 
Previously, we reported that microRNA‑155 (miR‑155) is up‑regulated in MS and by inflammatory cytokines in human 
brain endothelium, with consequent modulation of endothelial paracellular permeability. Here, we investigated the 
role of endothelial miR‑155 in leukocyte adhesion to the human cerebral microvascular endothelial cell line, hCMEC/
D3, under shear forces mimicking blood flow in vivo.
Results: Using a gain‑ and loss‑of‑function approach, we show that miR‑155 up‑regulation increases leukocyte firm 
adhesion of both monocyte and T cells to hCMEC/D3 cells. Inhibition of endogenous endothelial miR‑155 reduced 
monocytic and T cell firm adhesion to naïve and cytokines‑induced human brain endothelium. Furthermore, this 
effect is partially associated with modulation of the endothelial cell adhesion molecules VCAM1 and ICAM1 by 
miR‑155.
Conclusions: Our results suggest that endothelial miR‑155 contribute to the regulation of leukocyte adhesion at 
the inflamed BBB. Taken together with previous observations, brain endothelial miR‑155 may constitute a potential 
molecular target for treatment of neuroinflammation diseases.
Keywords: Blood–brain barrier, Cell adhesion molecules, Flow shear stress, Leukocyte adhesion, microRNA‑155, 
Neuroinflammation
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Background
Leukocyte recruitment from blood into tissues is a cru-
cial event in both physiological and pathological condi-
tions and is described as a multistep process involving 
leukocyte rolling, adhesion, crawling and diapedesis [1] 
under hemodynamic shear stress. In the central nerv-
ous system (CNS), firm leukocyte adhesion to the highly 
specialized brain endothelial cells forming the blood–
brain barrier (BBB) is important in immunosurveillance 
and plays a critical role in the pathogenesis of neuroin-
flammatory diseases such as multiple sclerosis (MS) [2]. 
Leukocyte adhesion occurs in postcapillary venules [3] 
as a result of specific interactions between leukocyte 
integrins, α4β1 (VLA-4) and αLβ2-integrin (LFA-1), and 
endothelial adhesion molecules, VCAM1 and ICAM1, 
respectively [4]. In MS, chemokines and proinflamma-
tory cytokines such as TNFα and IFNγ are secreted in 
the inflammatory loci thereby leading to VCAM1 and 
ICAM1 overexpression on activated brain endothelial 
cells [2]. Furthermore, it has been observed that both 
monocytes and T cells are present in the perivascular 
inflammatory infiltrates [5]. Despite numerous stud-
ies, the endothelial molecular controls on leukocyte 
firm adhesion to brain endothelium have not been fully 
elucidated.
MicroRNAs (miRs) are a class of highly conserved, 
single-stranded, non-coding RNA molecules (20–25 
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nucleotides), that modulate gene expression by repres-
sion of their target genes at the post-transcriptional level 
[6]. Recent studies have identified miRs as key regulators 
of a vast number of biological processes and disorders, 
including MS [7] and those regulating neurovascular 
function in inflammation [8], such as regulation of cell 
adhesion molecules and leukocyte trafficking across 
brain endothelium [9, 10].
MiR-155 is a multifunctional miR which plays a crucial 
role in physiological and pathological processes includ-
ing inflammation [11, 12]. MiR-155 expression is increased 
in brain endothelium in MS active lesions and proinflam-
matory cytokines, TNFα and IFNγ, up-regulate miR-155 
expression in the human cerebral microvascular endothelial 
cell line, hCMEC/D3 [13]. Furthermore, miR-155 overex-
pression in hCMEC/D3 cells increases endothelial perme-
ability and negatively affects expression of tight junctional 
molecules, whereas miR-155 inhibition is associated with 
decreased microvascular permeability [13]. In this study, we 
determined the role of human brain endothelial miR-155 in 
controlling T cell and monocyte firm adhesion to hCMEC/
D3 cells, an in vitro model of human brain endothelium [14], 
when subjected to shear forces mimicking blood flow at the 
venular vessel level in vivo. In addition, the effect of miR-155 
on the expression of the cell adhesion molecules VCAM1 
and ICAM1 in hCMEC/D3 cells was also investigated.
Methods
Cell culture
The hCMEC/D3 cell line [14] was used at passages 26–34 
and cultured in endothelial cell basal medium-2 (EGM-2) 
medium (Lonza, Walkersville, USA) and supplemented 
with the following components obtained from the man-
ufacturer: 0.025  % (v/v) rhEGF, 0.025  % (v/v) VEGF, 
0.025  % (v/v) IGF, 0.1  % (v/v) rhFGF, 0.1  % (v/v) genta-
mycin, 0.1 % (v/v) ascorbic acid, 0.04 % (v/v) hydrocorti-
sone and 2.5 % (v/v) foetal bovine serum (FBS), hereafter 
referred to as endothelial complete medium. hCMEC/D3 
cells were grown to confluence (~1 ×  105 cells/cm2) on 
tissue culture flasks coated with collagen from calf skin 
(Sigma, St. Louis, USA). The T cell line Jurkat from acute 
T cell leukaemia and the monocytic line THP1 from 
acute monocytic leukaemia were a kind gift from Dr. V 
Male (Cambridge University). Jurkat and THP1 cells were 
grown in suspension in RPMI 1640  W/GLUTAMAX I 
(Gibco®Invitrogen, Paisley,UK) culture medium (con-
taining 10  % FBS and 100  μg/ml streptomycin  +  100 
units/ml penicillin). All cell lines were maintained in a 
95 % humidified air and 5 % CO2 incubator at 37 °C.
MicroRNA transfection
hCMEC/D3 cells were grown to ~70  % confluence and 
transfected in antibiotic-free endothelial media. To 
introduce miR-155 precursor, hCMEC/D3 cells were 
transfected with 30  nM of pre-miR-155 or its con-
trol, scrambled-pre-miR (Ambion, Fischer Scientific 
UK), using Siport™ Polyamine Transfection Agent 
(Ambion) in Opti-mem®I (Gibco®) media for 24  h. For 
inhibition studies, 60  nM of anti-miR-155 or its con-
trol, scrambled-anti-miR (Dharmacon, Waltham, USA) 
was transfected using Lipofectamine® 2000 (Thermo 
Fisher Scientific, Carlsbad, USA) for 6 h, media was then 
changed with endothelial complete medium for 18  h. 
siGENOME SMARTpool siRNAs for human VCAM1 or 
siRNA control pool (ThermoFisher Scientific) were trans-
fected into hCMEC/D3 cells using Lipofectamine 2000® 
(Thermo Fisher Scientific).
Flow‑based leukocyte adhesion assay: live cell adhesion 
imaging under flow conditions
A flow-based adhesion assay previously described in 
Wu et  al. was used [10]. hCMEC/D3 cells were grown 
in Ibidi® μ-Slide VI0.4 (Ibidi® GmbH, Martinstreid, Ger-
many), transfected, treated or not with 1 ng/ml TNFα and 
IFNα for 24 h in static conditions and washed before flow 
adhesion assay. THP-1 and Jurkat cells (2 × 106 cells/ml) 
were labelled with CMFDA (5–chloromethylfluores-
ceindiacetate, Life Technologies, Eugene, USA) and were 
allowed to flow through the channel with endothelial 
monolayers and accumulate at 0.5  dyn/cm2 for 5  min. 
Then, the flow was increased to 1.5  dyn/cm2 (venular 
vessel wall shear stress) for 30 s to remove non-adhered 
leukocytes with endothelial complete media. Leukocyte-
endothelial interactions were recorded (Additional file 1: 
Video S1) for 5.5  min and firm leukocyte adhesion was 
quantified. Firm adhesion was defined by leukocytes that 
remained adhered on human brain endothelium in the 
field of view (FOV 640 × 480 μm) throughout the accu-
mulation time and after increasing the flow to 1.5  dyn/
cm2 and manually counted using Image J software in five 
different FOVs. Image acquisition was performed using 
a X10 objective of an inverted fluorescence microscope 
(Olympus IX70, Tokyo, Japan) controlled by the Image 
Pro Plus software (Media Cybernetics Inc. Bethesda, 
USA) using a Q-IMAGING QICAM FAST 1394 on a 
12-bit camera (40 images/min). For more details refer to 
Additional file 2: Fig. S1, Table S1 and Table S2.
ELISA for adhesion molecules
Brain endothelial expression of VCAM1 and ICAM1 was 
measured by cell-surface ELISA performed as previously 
described [15] using 2  μg/ml mouse primary antibody 
against VCAM1 or ICAM1 (R&D SYSTEMS, Abing-
don, UK) and the corresponding secondary antibodies 
conjugated to horseradish peroxidase. The optical den-
sity (OD) was then measured using a FLUOstar Optima 
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spectrometer (BMG LABTECH, Aylesbury, UK) at a 
wavelength of 450 nm.
Statistics
All data are presented as mean ± SEM from a number of 
independent experiments (n) with replicates specified in 
each legend. P values were calculated using paired Stu-
dent’s t tests. Statistically significant differences are pre-
sented as probability levels of P < 0.05 (*), P < 0.01 (**). 
Calculations and figures were performed using the statis-
tical software GraphPad Prism 5 (GraphPad Software).
Results
MiR‑155 modulates Jurkat and THP‑1 firm adhesion 
to hCMEC/D3 cells
We first investigated whether increased levels of miR-
155 in unstimulated brain endothelial cells affected firm 
leukocyte adhesion under shear stress. In human brain 
endothelium, miR-155 overexpression simulates, to a cer-
tain extent, the effect of proinflammatory cytokines [13], 
which are known to increase T cell firm adhesion [10]. We 
observed strong increase in adhesion of both T cell (Jur-
kat ~twofold increase) and monocyte (THP-1 ~threefold 
increase) to unstimulated hCMEC/D3 cells transfected 
with miR-155 precursor (pre-miR-155) compared with 
control (scrambled pre-miR) (Fig.  1a, b; Additional 
file  3: Video S2, Additional file  4: Video S3, Additional 
file  5: Video S4, Additional file  6: Video S5). Inhibition 
of endogenous miR-155 in hCMEC/D3 cells by transfec-
tion with anti-miR-155 reduced Jurkat and THP-1 firm 
adhesion to unstimulated brain endothelium compared 
to its control (scrambled anti-miR) (Fig. 1a and c; Addi-
tional file 7: Video S6, Additional file 8: Video S7, Addi-
tional file  9: Video S8, Additional file  10: Video S9). To 
better understand the contribution of endothelial miR-
155 in leukocyte adhesion, in the context of inflamma-
tion, we then explored the effect of miR-155 modulation 
on monocytic and T cell adhesion on brain endothelial 
cells stimulated with pro-inflammatory cytokines (TNFα 
and IFNγ at 1 ng/ml for 24 h), a treatment that increases 
brain endothelial miR-155 expression, hence monocytic 
and T cell adhesion (Fig. 1d, e; controls). Over-expression 
of miR-155 slightly increased shear resistant leukocyte 
adhesion to cytokine-treated brain endothelium com-
pared to control (cytokine-treated scrambled pre-miR) 
(Fig.  1 a, d; Additional file  11: Video S10, Additional 
Fig. 1 miR‑155 modulates Jurkat and THP‑1 firm adhesion to brain endothelial hCMEC/D3 cells. hCMEC/D3 cell monolayers were transfected 
with control scrambled Pre‑miR and Pre‑miR‑155 (a, c, d) or control scrambled Anti‑miR and Anti‑miR‑155 (a, c , e) followed by treatment with a 
combination of cytokines (TNFα + IFNγ) at 1 ng/ml for 24 h (a, d , e) or left unstimulated (a, b , c). a Representative images of shear‑resistant firmly 
adhered Jurkat and THP‑1 cells to hCMEC/D3 monolayer (field of view (FOV): 640 × 480 μm) used for quantification and b‑e analysis of shear‑
resistant firmly adhered Jurkat and THP‑1 cells to hCMEC/D3 expressed in number of cells/FOV. Experiments were carried out three to six times 
with five FOVs each. Data are mean ± SEM. Statistical analysis was performed using paired Student’s t test (*,#P < 0.05, **,##P < 0.01, #compared to 
unstimulated)
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file  12: Video S11, Additional file  13: Video S12, Addi-
tional file 14: Video S13). Reduction of endogenous miR-
155 reduced monocytic and T cell adhesion by ~50 and 
~35  %, respectively, to cytokine-stimulated endothelial 
cells when compared to control (cytokine-treated scram-
bled anti-miR) (Fig.  1a and e; Additional file  15: Video 
S14, Additional file  16: Video S15, Additional file  17: 
Video S16, Additional file 18: Video S17).
MiR‑155 modulates expression of cell adhesion molecules 
in hCMEC/D3 cells
To further elucidate the role of miR-155 in leuko-
cyte adhesion, we explored whether miR-155-induced 
changes in monocyte and T cell adhesion to endothe-
lium were associated with modulation of cell adhesion 
molecules VCAM1 and ICAM1 on the endothelial sur-
face, master mediators of leukocyte trafficking to the 
BBB [16]. ICAM1 plays a critical role in T cell adhesion 
as previously demonstrated [17], but VCAM1 is a main 
player in leukocyte adhesion and mediated both mono-
cyte and T cells adhesion to brain endothelium (Fig. 2a, 
b). Overexpression of miR-155 enhanced VCAM1 and 
ICAM1 levels on unstimulated hCMEC/D3 cells (Fig. 2c) 
whereas decreasing the levels of miR-155 caused a small 
reduction in VCAM1 and ICAM1 expression (Fig.  2d). 
No changes in VCAM1 or ICAM1 expression by miR-
155 were observed in cytokine-stimulated endothelium 
(Fig. 2e, f ).
Discussion
MiR-155 is strongly upregulated in cytokine-stimulated 
hCMEC/D3 cells and in EAE spinal cord vessels at acute 
stages of the disease, when the BBB is compromised [13]. 
The same study found that miR-155 acts as a novel reg-
ulator of barrier permeability by affecting expression of 
genes involved in modulation of tight junctions and cell 
to matrix interactions in human brain endothelium. In 
this study, we show that modulation of brain endothelial 
miR-155 levels led to significant changes on firm T cell 
and monocytic cell line adhesion to hCMEC/D3 cells. 
However, miR-155 induction of ICAM1 and VCAM1 
endothelial expression, while significant, was relatively 
small in unstimulated conditions, and, no changes in 
CAM expression by miR-155 were observed in cytokine-
treated cells. Therefore we consider that modulation of 
leukocyte adhesion to brain endothelium by endothelial 
miR-155 can only be partly accounted for by its effects 
in the expression of these adhesion molecules, in par-
ticular in the early stages of inflammation as miR-155 
is one of the earliest microRNAs to be rapidly induced 
a b
c d
e f
Fig. 2 miR‑155 modulates VCAM1 and ICAM1 expression on brain 
endothelial hCMEC/D3 cells. hCMEC/D3 cell monolayers were 
transfected with control siRNA (a, b) or scrambled Pre‑miR and 
Pre‑miR‑155 (c, e) or Anti‑miR and Anti‑miR‑155 (d, f) followed by 
treatment with a combination of cytokines (TNFα + IFNγ) at 1 ng/
ml for 24 h or left unstimulated. a, b Number of shear‑resistant firmly 
adhered Jurkat and THP‑1 cells to siVCAM1‑hCMEC/D3 monolayer 
per FOV (640 × 480 μm). c–f VCAM1 and ICAM1 expression levels 
were quantified by ELISA. Experiments were carried out three and 
four times with three replicates each. Data are mean ± SEM. Statisti‑
cal analysis was performed using paired Student’s t test (*,#P < 0.05, 
***,###P < 0.001, #compared to unstimulated)
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following inflammatory stimuli [13]. Indeed, increased 
levels of miR-155 enhanced by two fold the expression of 
two other adhesion-related genes, CCL5 and TNFSF10 
in hCMEC/D3 cells (Geo accession GSE44694, platform 
GPL6883).
Indirect mechanisms other than directly regulating 
expression of cell adhesion molecules could account 
for the effect of endothelial miR-155 on leukocyte firm-
adhesion. MiRs act by suppressing the expression of 
genes that contain the miR-target sequence in their 
mRNA and hence they directly reduce protein expres-
sion. Therefore, in order to modulate leukocyte adhe-
sion, miR-155 may regulate the expression of genes 
which control adhesion indirectly. In this context, it 
is possible that miR-155 could target NFκB pathway 
in brain endothelium as it does in HUVEC [18]. This 
pathway is activated by TNFα leading to the phos-
phorylation and breakdown of IκB which releases 
NFκB, allowing it to enter the nucleus and activate 
several genes involved in neuroinflammation, includ-
ing VCAM1 and ICAM1. IκB, the inhibitor of NFκB 
does not contain target sites for miR-155, but ‘Inhibi-
tor of nuclear factor kappa-B kinase-interacting pro-
tein’ (IKBIP) is a potential target for miR-155 (Diana 
Tools, miRTarbase), previously validated by proteom-
ics [19]. It is therefore conceivable that a reduction in 
IKBIP expression due to cytokine-induced miR-155 
would promote IκB kinase (IKK) to mediate phospho-
rylation and degradation of IκB, thereby leading to 
increased nuclear translocation of NFκB, with wide-
ranging down-stream effects including the one result-
ing in increased leukocyte adhesion. This goes hand 
in hand with our previous observation where inhibi-
tion of RelA, NFκB associated protein crucial for NFκB 
nuclear translocation and activation, decreased T cell 
adhesion by 60 % to hCMEC/D3 cells [10].
Another possible mechanism by which endothelial 
miR-155 may modulate leukocyte adhesion involves the 
small GTPase RhoA, a validated target of miR-155 [20]. 
Indeed, RhoA controls Rho-associated kinase (ROCK) 
which in turn modulates ICAM1 expression, cell adhe-
sion, the NFκB pathway [21]. In addition, RhoA is 
thought to affect leukocyte adhesion and migration by 
its actions in controlling the organisation of the brain 
endothelial cytoskeleton [22]. In hCMEC/D3, reduced 
levels of RhoA induced decreased VCAM1 expression 
and T cell adhesion [10]. It is certainly possible that miR-
155 targets more than one gene controlling either leu-
kocyte adhesion or endothelial activation, and the two 
genes discussed here both have several important down-
stream effects in controlling molecules involved in neu-
roinflammation and leukocyte adhesion.
Additional files
Additional file 1: Video S1. Representative video of flow‑based 
leukocyte adhesion assay using live cell imaging. Brightfield (Left Panel) 
and FITC (Right Panel) are displayed in parallel to show that the flow‑
based leukocyte adhesion assay used allows to perform live cell imaging 
recording both the endothelial monolayer by light microscopy and the 
fluorescent labelled leukocytes by fluorescent microscopy. The number 
of arrested JURKAT cells constantly increased along the channel of Ibidi® 
Slide VI, the yellow arrows (Right Panel) indicate arrested Jurkat cells. 
Objective 10x, phase‑contrast illumination and FITC channel (1 phase‑
contrast and 1 FITC), field of view 640 μm × 480 μm.
Additional file 2: Fig. S1, Table S1, Table S2.
Additional file 3: Video S2. Shear‑resistant firm adhesion of JURKAT cells 
to CONTROL Scrambled‑Pre‑miR transfected and unstimulated hCMECD3 
cells. JURKAT cells were pulled through the channel over hCMEC/D3 
monolayers under low shear (0.5 dyn/cm2). After 5 min, flow shear stress 
was increased (1.5 dyn/cm2) to challenge non‑firmly adherent JURKAT. The 
number of arrested JURKAT constantly increased during the accumula‑
tion phase and only the one that remained stationary on the endothelial 
monolayer were manually counted in 5 different FOV along the channel 
of Ibidi m‑Slide VI. FITC channel was used to count fluorescently firmly 
adhered Jurkat cells. Objective 10x, at 40 images per min (1 phase‑con‑
trast and 1 FITC), field of view 640 μm × 480 μm, recording time 5.5 min.
Additional file 4: Video S3. Shear‑resistant firm adhesion of JURKAT cells 
to Pre‑miR‑155 transfected and unstimulated hCMECD3 cells. JURKAT cells 
were pulled through the channel over hCMEC/D3 monolayers under low 
shear (0.5 dyn/cm2). After 5 min, flow shear stress was increased (1.5 dyn/
cm2) to challenge non‑firmly adherent JURKAT. The number of arrested 
JURKAT constantly increased during the accumulation phase and only 
the one that remained stationary on the endothelial monolayer were 
manually counted in 5 different FOV along the channel of Ibidi m‑Slide VI. 
FITC channel was used to count fluorescently firmly adhered Jurkat cells. 
Objective 10x, at 40 images per min (1 phase‑contrast and 1 FITC), field of 
view 640 μm × 480 μm, recording time 5.5 min.
Additional file 5: Video S4. Shear‑resistant firm adhesion of THP1 cells 
to CONTROL Scrambled‑Pre‑miR transfected and unstimulated hCMECD3 
cells. THP1 cells were pulled through the channel over hCMEC/D3 
monolayers under low shear (0.5 dyn/cm2). After 5 min, flow shear stress 
was increased (1.5 dyn/cm2) to challenge non‑firmly adherent THP1. The 
number of arrested THP1 constantly increased during the accumulation 
phase and only the one that remained stationary on the endothelial 
monolayer were manually counted in 5 different FOV along the channel 
of Ibidi m‑Slide VI. FITC channel was used to count fluorescently firmly 
adhered THP1 cells. Objective 10x, at 40 images per min (1 phase‑contrast 
and 1 FITC), field of view 640 μm × 480 μm, recording time 5.5 min.
Additional file 6: Video S5. Shear‑resistant firm adhesion of THP1 cells 
to Pre‑miR‑155 transfected and unstimulated hCMECD3 cells. THP1 cells 
Conclusions
Taken together, our findings support the notion that in 
neuroinflammatory conditions, miR-155 is itself up-regu-
lated and can promote many pro-inflammatory processes 
including leukocyte adhesion to brain endothelium. 
Because of their multiple effects on cellular processes, 
targeting an individual miR such as miR-155 for thera-
peutic purposes may lead to modulation of different acti-
vation pathways that promote inflammation. Together, 
these results reinforce the role of endothelial miR-155 
in the pathophysiology of the BBB, with a wide range of 
pro-inflammatory effects.
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were pulled through the channel over hCMEC/D3 monolayers under low 
shear (0.5 dyn/cm2). After 5 min, flow shear stress was increased (1.5 dyn/
cm2) to challenge non‑firmly adherent THP1. The number of arrested THP1 
constantly increased during the accumulation phase and only the one 
that remained stationary on the endothelial monolayer were manually 
counted in 5 different FOV along the channel of Ibidi m‑Slide VI. FITC 
channel was used to count fluorescently firmly adhered THP1 cells. Objec‑
tive 10x, at 40 images per min (1 phase‑contrast and 1 FITC), field of view 
640 μm × 480 μm, recording time 5.5 min.
Additional file 7: Video S6. Shear‑resistant firm adhesion of JURKAT cells 
to CONTROL Scrambled‑Anti‑miR transfected and unstimulated hCMECD3 
cells. JURKAT cells were pulled through the channel over hCMEC/D3 
monolayers under low shear (0.5 dyn/cm2). After 5 min, flow shear stress 
was increased (1.5 dyn/cm2) to challenge non‑firmly adherent JURKAT. The 
number of arrested JURKAT constantly increased during the accumula‑
tion phase and only the one that remained stationary on the endothelial 
monolayer were manually counted in 5 different FOV along the channel 
of Ibidi m‑Slide VI. FITC channel was used to count fluorescently firmly 
adhered Jurkat cells. Objective 10x, at 40 images per min (1 phase‑con‑
trast and 1 FITC), field of view 640 μm × 480 μm, recording time 5.5 min.
Additional file 8: Video S7. Shear‑resistant firm adhesion of JURKAT cells 
to Anti‑miR‑155 transfected and unstimulated hCMECD3 cells. JURKAT 
cells were pulled through the channel over hCMEC/D3 monolayers under 
low shear (0.5 dyn/cm2). After 5 min, flow shear stress was increased 
(1.5 dyn/cm2) to challenge non‑firmly adherent JURKAT. The number of 
arrested JURKAT constantly increased during the accumulation phase and 
only the one that remained stationary on the endothelial monolayer were 
manually counted in 5 different FOV along the channel of Ibidi m‑Slide VI. 
FITC channel was used to count fluorescently firmly adhered Jurkat cells. 
Objective 10x, at 40 images per min (1 phase‑contrast and 1 FITC), field of 
view 640 μm × 480 μm, recording time 5.5 min.
Additional file 9: Video S8. Shear‑resistant firm adhesion of THP1 
cells to CONTROL Scrambled‑Anti‑miR transfected and unstimulated 
hCMECD3 cells. THP1 cells were pulled through the channel over hCMEC/
D3 monolayers under low shear (0.5 dyn/cm2). After 5 min, flow shear 
stress was increased (1.5 dyn/cm2) to challenge non‑firmly adherent THP1. 
The number of arrested THP1 constantly increased during the accumula‑
tion phase and only the one that remained stationary on the endothelial 
monolayer were manually counted in 5 different FOV along the channel 
of Ibidi m‑Slide VI. FITC channel was used to count fluorescently firmly 
adhered THP1 cells. Objective 10x, at 40 images per min (1 phase‑contrast 
and 1 FITC), field of view 640 μm × 480 μm, recording time 5.5 min.
Additional file 10: Video S9. Shear‑resistant firm adhesion of THP1 cells 
to Anti‑miR‑155 unstimulated transfected and unstimulated hCMECD3 
cells. THP1 cells were pulled through the channel over hCMEC/D3 
monolayers under low shear (0.5 dyn/cm2). After 5 min, flow shear stress 
was increased (1.5 dyn/cm2) to challenge non‑firmly adherent THP1. The 
number of arrested THP1 constantly increased during the accumulation 
phase and only the one that remained stationary on the endothelial 
monolayer were manually counted in 5 different FOV along the channel 
of Ibidi m‑Slide VI. FITC channel was used to count fluorescently firmly 
adhered THP1cells. Objective 10x, at 40 images per min (1 phase‑contrast 
and 1 FITC), field of view 640 μm × 480 μm, recording time 5.5 min.
Additional file 11: Video S10. Shear‑resistant firm adhesion of JURKAT 
cells to CONTROL Scrambled‑Pre‑miR transfected and stimulated with 
TNFα and IFNγ hCMECD3 cells. JURKAT cells were pulled through the 
channel over hCMEC/D3 monolayers under low shear (0.5 dyn/cm2). 
After 5 min, flow shear stress was increased (1.5 dyn/cm2) to challenge 
non‑firmly adherent JURKAT. The number of arrested JURKAT constantly 
increased during the accumulation phase and only the one that remained 
stationary on the endothelial monolayer were manually counted in 5 dif‑
ferent FOV along the channel of Ibidi m‑Slide VI. FITC channel was used to 
count fluorescently firmly adhered Jurkat cells. Objective 10x, at 40 images 
per min (1 phase‑contrast and 1 FITC), field of view 640 μm × 480 μm, 
recording time 5.5 min.
Additional file 12: Video S11. Shear‑resistant firm adhesion of THP1 
cells to CONTROL Scrambled‑Pre‑miR transfected and stimulated with 
TNFα and IFNγ hCMECD3 cells. THP1 cells were pulled through the 
channel over hCMEC/D3 monolayers under low shear (0.5 dyn/cm2). 
After 5 min, flow shear stress was increased (1.5 dyn/cm2) to challenge 
non‑firmly adherent THP1. The number of arrested THP1 constantly 
increased during the accumulation phase and only the one that remained 
stationary on the endothelial monolayer were manually counted in 5 dif‑
ferent FOV along the channel of Ibidi m‑Slide VI. FITC channel was used to 
count fluorescently firmly adhered THP1 cells. Objective 10x, at 40 images 
per min (1 phase‑contrast and 1 FITC), field of view 640 μm × 480 μm, 
recording time 5.5 min.
Additional file 13: Video S12. Shear‑resistant firm adhesion of THP1 
cells to Pre‑miR‑155 transfected and stimulated with TNFα and IFNγ 
hCMECD3 cells. THP1 cells were pulled through the channel over hCMEC/
D3 monolayers under low shear (0.5 dyn/cm2). After 5 min, flow shear 
stress was increased (1.5 dyn/cm2) to challenge non‑firmly adherent THP1. 
The number of arrested THP1 constantly increased during the accumula‑
tion phase and only the one that remained stationary on the endothelial 
monolayer were manually counted in 5 different FOV along the channel 
of Ibidi m‑Slide VI. FITC channel was used to count fluorescently firmly 
adhered THP1 cells. Objective 10x, at 40 images per min (1 phase‑contrast 
and 1 FITC), field of view 640 μm × 480 μm, recording time 5.5 min.
Additional file 14: Video S13. Shear‑resistant firm adhesion of JURKAT 
cells to CONTROL Scrambled‑Anti‑miR transfected and stimulated with 
TNFα and IFNγ hCMECD3 cells. JURKAT cells were pulled through the 
channel over hCMEC/D3 monolayers under low shear (0.5 dyn/cm2). 
After 5 min, flow shear stress was increased (1.5 dyn/cm2) to challenge 
non‑firmly adherent JURKAT. The number of arrested JURKAT constantly 
increased during the accumulation phase and only the one that remained 
stationary on the endothelial monolayer were manually counted in 5 dif‑
ferent FOV along the channel of Ibidi m‑Slide VI. FITC channel was used to 
count fluorescently firmly adhered Jurkat cells. Objective 10x, at 40 images 
per min (1 phase‑contrast and 1 FITC), field of view 640 μm × 480 μm, 
recording time 5.5 min.
Additional file 15: Video S14. Shear‑resistant firm adhesion of JURKAT 
cells to CONTROL Scrambled‑Anti‑miR transfected and stimulated with 
TNFα and IFNγ hCMECD3 cells. JURKAT cells were pulled through the 
channel over hCMEC/D3 monolayers under low shear (0.5 dyn/cm2). 
After 5 min, flow shear stress was increased (1.5 dyn/cm2) to challenge 
non‑firmly adherent JURKAT. The number of arrested JURKAT constantly 
increased during the accumulation phase and only the one that remained 
stationary on the endothelial monolayer were manually counted in 5 dif‑
ferent FOV along the channel of Ibidi m‑Slide VI. FITC channel was used to 
count fluorescently firmly adhered Jurkat cells. Objective 10x, at 40 images 
per min (1 phase‑contrast and 1 FITC), field of view 640 μm × 480 μm, 
recording time 5.5 min.
Additional file 16: Video S15. Shear‑resistant firm adhesion of THP1 
cells to CONTROL Scrambled‑Anti‑miR transfected and stimulated with 
TNFα and IFNγ hCMECD3 cells. THP1 cells were pulled through the 
channel over hCMEC/D3 monolayers under low shear (0.5 dyn/cm2). 
After 5 min, flow shear stress was increased (1.5 dyn/cm2) to challenge 
non‑firmly adherent THP1. The number of arrested THP1 constantly 
increased during the accumulation phase and only the one that remained 
stationary on the endothelial monolayer were manually counted in 5 dif‑
ferent FOV along the channel of Ibidi m‑Slide VI. FITC channel was used to 
count fluorescently firmly adhered THP1 cells. Objective 10x, at 40 images 
per min (1 phase‑contrast and 1 FITC), field of view 640 μm × 480 μm, 
recording time 5.5 min.
Additional file 17: Video S16. Shear‑resistant firm adhesion of THP1 
cells to Anti‑miR‑155 transfected and stimulated with TNFα and IFNγ hCM‑
ECD3 cells. THP1 cells were pulled through the channel over hCMEC/D3 
monolayers under low shear (0.5 dyn/cm2). After 5 min, flow shear stress 
was increased (1.5 dyn/cm2) to challenge non‑firmly adherent THP1. The 
number of arrested THP1 constantly increased during the accumulation 
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phase and only the one that remained stationary on the endothelial 
monolayer were manually counted in 5 different FOV along the channel 
of Ibidi m‑Slide VI. FITC channel was used to count fluorescently firmly 
adhered THP1 cells. Objective 10x, at 40 images per min (1 phase‑contrast 
and 1 FITC), field of view 640 μm × 480 μm, recording time 5.5 min.
Additional file 18: Video S17. Shear‑resistant firm adhesion of THP1 
cells to Anti‑miR‑155 transfected and stimulated with TNFα and IFNγ 
hCMECD3 cells. THP1 cells were pulled through the channel over hCMEC/
D3 monolayers under low shear (0.5 dyn/cm2). After 5 min, flow shear 
stress was increased (1.5 dyn/cm2) to challenge non‑firmly adherent THP1. 
The number of arrested THP1 constantly increased during the accumula‑
tion phase and only the one that remained stationary on the endothelial 
monolayer were manually counted in 5 different FOV along the channel 
of Ibidi m‑Slide VI. FITC channel was used to count fluorescently firmly 
adhered THP1 cells. Objective 10x, at 40 images per min (1 phase‑contrast 
and 1 FITC), field of view 640 μm × 480 μm, recording time 5.5 min.
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